Clinical Trial

Empagliflozin in Hypertrophic Cardiomyopathy

Study acronym: EMPA-REPAIR
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The proposed intervention will be administration of empagliflozin at a standard dose of 10 mg daily for a period of 12 months. Patients with diagnosed diabetes will be excluded from the study. Patients (n = 250) will be randomized in a double-blind fashion to empagliflozin or placebo group. The primary endpoint of the study will be the change in peak oxygen uptake (VO2 max) measured in a cardiopulmonary exercise test. VO2max is an objective indicator of physical performance and will be evaluated before and after empagliflozin or placebo treatment.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-12-21; most recent amendment 2026-03-11.
Status change: Recruiting → Active, Not Recruiting 2026-03-11
Status change: Not Yet Recruiting → Recruiting 2023-10-24
Trial Details
NCT Number NCT05182658
Lead Sponsor National Institute of Cardiology, Warsaw, Poland
Collaborators: Medical University of Bialystok, University of Eastern Finland, Amsterdam UMC, location VUmc
Conditions Hypertrophic Cardiomyopathy, Heart Failure
Enrollment 250 participants
Start Date 2022-06-01
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-12